Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Kansas: - Cancer Center of Kansas - Chanute — Chanute, Kansas
- Cancer Center of Kansas - Dodge City — Dodge City, Kansas
- Cancer Center of Kansas - El Dorado — El Dorado, Kansas
- HaysMed — Hays, Kansas
- Cancer Center of Kansas-Independence — Independence, Kansas
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Kansas: - Kansas University Medical Center — Westwood, Kansas
Phase 2, Phase 3 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloi…
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in Kansas: - University of Kansas Cancer Center — Westwood, Kansas
Phase 3 Recruiting Academic/Other
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and a…
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT ID: NCT07223814
Sites in Kansas: - US-Kansas City KS-KUMC — Kansas City, Kansas
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 2 Recruiting NIH
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibit…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06311227
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 2 Recruiting Industry
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\]…
Sponsor: Bio-Path Holdings, Inc.
NCT ID: NCT02781883
Sites in Kansas: - University of Kansas Cancer Center — Fairway, Kansas
Phase 1, Phase 2 Recruiting Academic/Other
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. T…
Sponsor: Leland Metheny
NCT ID: NCT03104491
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Sponsor: BeOne Medicines
NCT ID: NCT06697184
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Kansas: - The University of Kansas Medical Center Research Institute — Fairway, Kansas
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Kansas: - The University of Kansas Cancer Center — Kansas City, Kansas
Phase 1 Recruiting NIH
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886049
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 1 Recruiting Industry
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Sponsor: Orca Biosystems, Inc.
NCT ID: NCT03802695
Sites in Kansas: - The University of Kansas Hospital — Kansas City, Kansas
Phase 1 Recruiting Industry
This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of…
Sponsor: Marker Therapeutics, Inc.
NCT ID: NCT06552416
Sites in Kansas: - KU Cancer Center — Kansas City, Kansas
Phase 1 Recruiting Industry
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemothe…
Sponsor: Celyad Oncology SA
NCT ID: NCT04167696
Sites in Kansas: - University of Kansas Cancer Center — Fairway, Kansas
Phase 1 Recruiting Academic/Other
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targe…
Sponsor: University of Kansas Medical Center
NCT ID: NCT06879340
Sites in Kansas: - University of Kansas Cancer Center — Westwood, Kansas
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Kansas: - University of Kansas — Westwood, Kansas
Recruiting Industry
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07143669
Sites in Kansas: - University of Kansas Medical Center — Kansas City, Kansas